Synonym provides infrastructure for the bioeconomy. The company helps turn breakthroughs in the lab into products on the market by scaling biomanufacturing infrastructure.

Synonym

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Austin Che

Tom Knight

Jason Kelly

Barry Canton

Reshma Shetty

Ginkgo Bioworks Holdings, Inc.

Synonym is a company that builds and scales infrastructure enabling the commercialization and manufacture of bioproducts—accelerating the world’s transition to better, more sustainable ways of making the items the world needs. It believes that products created using biology will represent the next manufacturing revolution, transforming crucial elements of supply chains across multiple sectors and helping to catalyze a decarbonized future. Using the industry’s most dynamic manufacturing database and a suite of proprietary resources, Synonym works as the strategic biomanufacturing partner for companies building these next-generation bioproducts, helping them to expand and scale seamlessly. 

Giant Ventures

Blue Horizon Corporation

Zero Infinity Partners

Thia Ventures

Andreessen Horowitz

Ron Zori

FJ Labs

Have you checked out Protein Production Technology International's latest issue? Our team was thrilled to see Proteo Biotech featured as an Innovation Spotlight!

It's great to see companies like Proteo Biotech making strides in fermentation innovation. Their work on developing a revolutionary protein source from yeast offers a sustainable and nutritious solution to feed the growing global population. By leveraging precision fermentation, Proteo is creating versatile, yeast-derived proteins that mimic the textural and sensory qualities of animal-derived proteins. This advancement not only addresses critical environmental challenges but also enhances the nutritional profile of food products.

The Synonym team is eager to follow their progress and see the impact they make.

Check out the full feature linked in the comments below!

#biomanufacturing #bioeconomy #fermentation #precisionfermentation #sustainability #climatetech

When is the right time for techno-economic analysis (TEA)? In our strain engineering webinar last week, our panelists emphasized that it's never too early to begin this crucial step.

Strain engineering and techno-economic analysis (TEA) are two important pieces of the scale-up puzzle. Understanding what your unit economics look like at different scales and what combination of fermentation parameters is required to achieve economic viability helps you focus R&D resources on the most important efforts. Starting TEA early ensures a smoother path to commercialization and helps achieve optimal outcomes.

Looking to get started with a TEA? Contact our team today and we'll be in touch.

#bioeconomy #biomanufacturing #strainengineering #climatetech #fermentation #precisionfermentation #technoeconomicanalysis

A big thank you to everyone who joined us yesterday for our webinar on the critical role of strain engineering in biomanufacturing! It was a fantastic session with great insights from our panel of experts from Enduro, EV Biotech, Vectron Biosolutions AS, and SynBioBeta.

Missed the webinar? No worries! Reach out to our team at contact@synonym.bio and we'll have you covered.

We’re excited to continue these kinds of conversations and bring you more insightful events in the future. Follow Synonym to stay connected for updates on upcoming webinars and discussions!

#bioeconomy #biomanufacturing #webinar #strainengineering #innovation #fermentation #precisionfermentation

How will we overcome biomanufacturing's scale-cost paradox? 

Standardization, modularization, and productization. Check out the clip below of our co-founder and chief business officer, Joshua Lachter speaking on the main stage at this year's SynBioBeta conference alongside Boston Consulting Group (BCG)'s Jean-Francois Bobier. The two dove deep into the recent report our teams co-authored that highlights biomanufacturing's massive potential in the coming decades.

Looking forward to more of this at the SynBioBeta conference next year!

#synbiobeta #biomanufacturing #scaleup #bioeconomy #fermentation #precisionfermentation #climatetech #deeptech #synbio

Only one more day to sign up for tomorrow's webinar! Don’t miss out on our discussion about the crucial role that strain engineering plays in commercializing bioproducts.

📅 Date: July 17, 2024
🕒 Time: 10am to 11am EDT (4pm to 5pm CET)
📍 Register here: https://lnkd.in/dAJSeYaA

#synbio #bioeconomy #biomanufacturing #sustainability #biotech  #fermentation #precisionfermentation

EV Biotech Vectron Biosolutions AS Enduro SynBioBeta

Last week, we had the privilege of attending a landmark event at the White House focused on Safe, Secure, and Sustainable Supply Chains through Biomanufacturing. Organized by the White House Office of Science and Technology Policy's, the event emphasized the significant achievements and future potential of President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation.

It was great to be surrounded by so many key stakeholders of the US bioeconomy and to celebrate the remarkable progress made by the Biden-Harris Administration.

For the full list of achievements, including investments from the U.S. Department of Energy (DOE), United States Department of Defense, National Science Foundation (NSF), and USDA, check out fact sheet at  https://lnkd.in/e2FNTcwi

Events like this one make our team excited about the ongoing dialogue and collaborative efforts to advance the US bioeconomy.

#bioeconomy #biomanufacturing #fermentation #precisionfermentation #policy #whitehouse #deeptech #sustainability

Metric
Company Name	Synonym	Ginkgo Bioworks Holdings, Inc.
Symbol		DNA
MSH ID	BIO:SYNONYM	COM:GINKGOBIOWORKS
Market	PRIVATE	STOCKS
Sector	Technology	Healthcare
Industry	Biotechnology	Biotechnology
Country	US	US
Stage		Grant
Employee Count	27	1.22K
Website	synonym.bio	ginkgobioworks.com
LinkedIn	synonymbio	ginkgo-bioworks
Founders

Metric
Market Cap		725.64M
Enterprise Value
Monthly Web Traffic		20.69K
Web Traffic Growth		-0.17
Valuation
Raised Capital

Metric
Revenue		251.46M
Revenue (LTM)
Revenue (NTM)
Gross Profit		142.64M
EBITDA		-600.68M
Operating Income		-672.23M
Net Income		-892.87M
EPS		-0.46
Diluted EPS		-0.46
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.75
Operating Profit Margin		-3.34
EBITDA Margin		-2.39
Net Profit Margin		-3.55
Return on Equity		-0.65
Return on Assets		-0.54
Return on Capital Employed		-0.51

BIO:SYNONYM

Synonym

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-2.78
P/B Ratio		1.90
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		93.70
EV Multiple		-1.34

Metric
Days Sales Outstanding		73.17
Days Payables Outstanding		50.57
Days Inventory Outstanding		0.27
Operating Cycle		46.33
Cash Conversion Cycle		-7.39
Asset Turnover		0.15

Metric
Operating Cash Flow		-295.50M
Free Cash Flow		-336.30M
Cash Flow to Debt		-0.63
Operating Cash Flow/Sales		-1.14
Free Cash Flow Yield		-0.16

Metric
Cash & Equivalents		948.86M
Accounts Receivable		50.07M
Inventory		46K
Goodwill		49.24M
Debt to Capitalization		0.35
Debt to Assets		0.20
Current Ratio		6.78
Quick Ratio		5.98

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.94
R&D to Revenue		2.05
SG&A to Revenue		1.32